Floatz logo

SRY-BOX TRANSCRIPTION FACTOR 2

HER2 Negative Breast Carcinoma

University of Washingtonprotein_peptidePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

191 Active assets in the HER2 Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Palbociclib
Helwan University
Phase 2BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2BBB
Atezolizumab
TransThera Sciences (Nanjing), Inc.
Phase 2BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 50 →

Same molecule, other indications

SRY-BOX TRANSCRIPTION FACTOR 2 is also rated in:

breast cancerDormant
B
Indicative ·
58 / 100
View asset →
hormone receptor-positive breast cancerDormant
CCC
Indicative ·
53 / 100
View asset →
triple-negative breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →